We compiled a systematic review protocol and registered it with the PROSPERO database (CRD42013003610). That can certainly be said for the comprehensive front-page article the New York Times ran this Saturday, April 5, on the high cost of new type 1 diabetes tools. Discount rates of 3% per annum were applied to the costs and the clinical outcomes. As such, patients often choose to settle for suboptimal glucose control in order to prevent hypoglycaemic events. In 2012 alone, 1.7 million people aged 20 years or older were newly diagnosed with diabetes. The study was conducted in a large metropolitan US city from April 1997 through April 2000. DAFNE was found to generate an average of 0.0294 additional quality-adjusted life years for an additional cost of £426 per patient, leading to an incremental cost-effectiveness ratio of £14 400 compared with no DAFNE.
Recommendations for the format of this study are made, including extending the scope to cover recent treatment developments